BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35451606)

  • 1. Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Cornud F; Lefevre A; Camparo P; Barat M; Dumonceau O; Galiano M; Flam T; Soyer P; Barral M
    Eur Radiol; 2022 Nov; 32(11):7504-7512. PubMed ID: 35451606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI-directed high-frequency (29MhZ) TRUS-guided biopsies: initial results of a single-center study.
    Cornud F; Lefevre A; Flam T; Dumonceau O; Galiano M; Soyer P; Camparo P; Barral M
    Eur Radiol; 2020 Sep; 30(9):4838-4846. PubMed ID: 32350662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
    Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
    Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 5. The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidée par micro-échographie, quel bénéfice ? Une analyse lésion par lésion.
    Martel P; Rakauskas A; Dagher J; La Rosa S; Meuwly JY; Roth B; Valerio M
    Prog Urol; 2022 Jun; 32(6S1):6S26-6S32. PubMed ID: 36719643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic performance of microUltrasound at MRI-guided confirmatory biopsy in patients under active surveillance for low-risk prostate cancer.
    Maffei D; Fasulo V; Avolio PP; Saitta C; Paciotti M; De Carne F; Colombo P; Pasini L; De Zorzi SZ; Saita A; Hurle R; Lazzeri M; Guazzoni GF; Casale P; Buffi NM; Lughezzani G
    Prostate; 2023 Jun; 83(9):886-895. PubMed ID: 36960788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer.
    Rudolph MM; Baur ADJ; Haas M; Cash H; Miller K; Mahjoub S; Hartenstein A; Kaufmann D; Rotzinger R; Lee CH; Asbach P; Hamm B; Penzkofer T
    Eur Radiol; 2020 Aug; 30(8):4262-4271. PubMed ID: 32219507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
    Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
    World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 16. Transrectal ultrasound-guided targeted biopsy of transition zone prostate cancer under cognitive registration with prebiopsy MRI and sonographic findings.
    Won SY; Cho NH; Choi YD; Park SY
    Clin Radiol; 2020 Feb; 75(2):157.e21-157.e27. PubMed ID: 31677880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer.
    Klotz L; Andriole G; Cash H; Cooperberg M; Crawford ED; Emberton M; Gomez-Sancha F; Klein E; Lughezzani G; Marks L; Montorsi F; Salomon G; Sanchez-Salas R; Shore N; Taneja S
    Contemp Clin Trials; 2022 Jan; 112():106618. PubMed ID: 34728381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
    Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
    Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.